Monoclonal Antibody Eradicates Tumors In Animal Models.(Brief Article)

2001 JUL 11 - (NewsRx.com & NewsRx.net) --

Genmab A/S (CSE:GEN and Neuer Markt:GE9D) announced that its HuMax(TM)-EGFr, a human monoclonal antibody targeting the epidermal growth factor receptor (EGFr), demonstrated potent anti-tumor effects in in vivo mouse studies.

In comparison to previously published in vivo studies using other companies' anti-EGFr antibodies, Genmab's HuMax-EGFr was more effective at eliminating established tumors and did so at lower doses with less frequent dosing. When administered a day after introducing human tumor cells into mouse models, HuMax-EGFr was capable of completely preventing tumor formation at a dose of 50 mcg. Furthermore, HuMax-EGFr was also capable of eradicating well-established tumors in the mice at a dose as low as 125 mcg.

Unlike earlier anti-EGFr monoclonal antibodies, HuMax-EGFr is composed entirely of human sequence protein.

Such fully human antibodies are expected to avoid the complications sometimes caused by antibodies derived partially from mice.

Jan G.J. van de Winkel, PhD, Genmab, and professor of immunology, Utrecht University, Netherlands, presented these data at the 18th International Conference on ...